# Voriconazole For Chronic Bronchopulmonary Aspergillosis

> **NCT00159822** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 48 (actual)

## Conditions studied

- Aspergillosis

## Interventions

- **DRUG:** Voriconazole

## Key facts

- **NCT ID:** NCT00159822
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2010-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00159822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00159822, "Voriconazole For Chronic Bronchopulmonary Aspergillosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00159822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*